# Rydapt (midostaurin) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/midostaurin

> The FDA approved Rydapt (midostaurin), sponsored by NOVARTIS AG (NVS), on April 28, 2017.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Rydapt (midostaurin) |
| Codes | PKC412 |
| Sponsor | NOVARTIS AG (NVS) https://sec-api.dev/companies/nvs/catalysts |
| Indications | [FLT3-mutated Acute Myeloid Leukemia](https://sec-api.dev/indications/flt3-mutated-acute-myeloid-leukemia) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### April 28, 2017: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207997 ORIG-2 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170428, review_priority PRIORITY; sponsor_name NOVARTIS; product RYDAPT (MIDOSTAURIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207997%22
- openFDA Drugs@FDA: "NDA207997 ORIG-1 (Efficacy): submission_status AP, submission_status_date 20170428, review_priority PRIORITY; sponsor_name NOVARTIS; product RYDAPT (MIDOSTAURIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207997%22

### November 24, 2020: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA207997 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20201124, review_priority PRIORITY; sponsor_name NOVARTIS; product RYDAPT (MIDOSTAURIN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207997%22

### May to Aug 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: FLT3-mutated Acute Myeloid Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03591510 (A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-05-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT03591510

### May 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: FLT3-mutated Acute Myeloid Leukemia.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03591510 (A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-05-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." https://clinicaltrials.gov/study/NCT03591510

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/midostaurin.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Rydapt (midostaurin) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/midostaurin

```bibtex
@misc{secapidev_pdufa_midostaurin_20261116,
  title        = {Rydapt (midostaurin) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/midostaurin}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_midostaurin_20261116","title":"Rydapt (midostaurin) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/midostaurin","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
